The in vitro activity of enoxacin was tested against 1000 clinical isolates of gram-positive and gram-negative microorganisms and compared with that of norfloxacin and amikacin. The MIC90 of enoxacin was 1 mg/l forEnterobacteriaceae, 2.6 mg/l forPseudomonas aeruginosa and 6.2 mg/l forStaphylococcus aureus. The inoculum effect was minimal. The MlCs and MBCs forPseudomonas aeruginosa strains were significantly affected by the addition of calcium and magnesium ions. Synergy was occasionally observed between enoxacin and the antibiotics tested; antagonism was rare.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Shimizu, M., Takase, S., Nakamura, S., Katae, H., Minami, A., Nakata, K., Sakaguchi, Y.: AT-2266, a new oral antipseudomonal agent. In: Nelson, J. D., Grassi, C. (ed.): Current chemotherapy and infectious disease. American Society for Microbiology, Washington D. C., 1980, p. 451–454.
Bauernfeind, A., Petermuller, O.: In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. European Journal of Clinical Microbiology 1983, 2: 111–115.
Nakamura, S., Takase, V., Kurobe, N., Kashimoto, S., Shimizu, M.: Pharmacological properties of AT-2266. In: Nelson, J. D., Grassi, C. (ed.): Current chemotherapy and infectious disease. American Society for Microbiology, Washington D.C., 1980, p. 456–453.
Gavan, T. L., Barry, A. L.: Microdilution test procedures. In: Lennette, E. H., Balows, A., Hausler, W. J. Jr., Truant, J. P. (ed.): Manual of clinical microbiology. American Society for Microbiology, Washington D.C., 1980, p. 459–462.
Stratton, C. W., Reller, L. B.: Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. Journal of Infectious Diseases 1977, 136: 187–195.
Krogstad, D. J., Moellering, R. C.: Combinations of antibiotics, mechanisms of interaction against bacteria. In: Lorian, V. (ed.): Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, 1980, p. 298–341.
Bulliard, G., Schuyteneer, F., Van der Auwera, P.: Comparison of the rates of mutational resistance of MK-0366, oxolinic, nalidixic acids, and cinoxacin onPseudomonas aeruginosa andStaphylococcus aureus. Drugs under Experimental and Clinical Research 1983, IX: 61–65.
Tenney, J. H., Maack, R. W., Chippendale, G. R.: Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrobial Agents and Chemotherapy 1983, 23: 188–189.
Chin, N. X., Neu, H. C.: In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides and trimethoprim. Antimicrobial Agents and Chemotherapy 1983, 24: 754–763.
Ronald, A. R., Turck, M., Petersdorf, R. G.: A critical evaluation of nalidixic acid in urinary tract infections. New England Journal of Medicine 1966, 275: 1081–1084.
About this article
Cite this article
van der Auwera, P., de Moor, G., Lacroix, G. et al. In vitro activity of enoxacin compared with norfloxacin and amikacin. Eur. J, Clin. Microbiol. 4, 55–58 (1985). https://doi.org/10.1007/BF02148662
- Internal Medicine
- Clinical Isolate